Overview

Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, multicenter, Phase II clinical study of AC591 in preventing Oxaliplatin-Induced Peripheral Neuropathy
Phase:
PHASE2
Details
Lead Sponsor:
Shandong New Time Pharmaceutical Co., LTD